Skip to main content

Peer Review reports

From: Study design and rationale for a randomised, placebo-controlled, double-blind study to assess the efficacy of selumetinib (AZD6244; ARRY-142886) in combination with dacarbazine in patients with metastatic uveal melanoma (SUMIT)

Original Submission
9 Jan 2015 Submitted Original manuscript
Author responded Author comments
Resubmission - Version 2
Submitted Manuscript version 2
Author responded Author comments
Reviewed Reviewer Report
Reviewed Reviewer Report
Reviewed Reviewer Report
Resubmission - Version 3
Submitted Manuscript version 3
Reviewed Reviewer Report
Resubmission - Version 4
Submitted Manuscript version 4
Publishing
26 May 2015 Editorially accepted
10 Jun 2015 Article published 10.1186/s12885-015-1470-z

You can find further information about peer review here.

Back to article page